On This Day in Health: March 22, 2023
On March 22, 2023, the United States Food and Drug Administration granted accelerated approval to retifanlimab, marketed as Zynyz, for adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The decision added an immune-based treatment for an uncommon and aggressive skin cancer. Its scope concerned advanced disease, rather than every skin cancer or every stage of Merkel cell carcinoma. The approval pathway relied on tumor response and the duration of those responses, with further work needed to confirm clinical benefit. The date marks a defined addition to oncology care within a continuing research program.
Retifanlimab is a monoclonal antibody directed against PD-1, an immune checkpoint that helps regulate the activity of certain immune cells. Blocking that signal can allow an immune response against cancer to become more active. The approach differs from directly delivering a conventional chemotherapy drug to a tumor. It belongs to a broader development in cancer medicine in which treatment can alter interactions between a tumor and the immune system. That biological explanation provides context for the medicine, but the approval still depended on observed clinical outcomes rather than on the mechanism alone.
Evidence came from PODIUM-201, an open-label study without a randomized comparison group. The efficacy analysis included 65 patients with metastatic or recurrent locally advanced disease who had not previously received systemic treatment for advanced Merkel cell carcinoma. Independent reviewers assessed tumor changes using established response criteria. Approximately fifty-two percent had an objective response, including complete responses in eighteen percent. Researchers also examined how long responses lasted. Those measures showed activity in the studied population, but the absence of a control group limited the comparisons that could be made. A response rate is not the same measure as improved overall survival.
The safety evaluation included a larger group of 105 patients and identified adverse effects such as fatigue, musculoskeletal pain, itching, and other problems. Immune-based treatment also requires attention to inflammation that can affect healthy organs. These considerations were part of the regulatory context, not separate from the milestone. March 22 illustrates how accelerated approval can bring a treatment into use based on evidence of an important effect while preserving a requirement for continued verification. The historical meaning is strongest when the pathway is described accurately: an additional option reached authorization for a specific advanced cancer, supported by responses observed in a clinical study. It remained part of an evolving field in which later evidence could refine understanding of benefit, risk, and the most appropriate role of the medicine.
The indication concerned advanced Merkel cell carcinoma. It did not extend to all forms of skin cancer.
Retifanlimab targets the PD-1 immune checkpoint. Its mechanism can increase immune activity against a tumor.
PODIUM-201 was an open-label, single-arm study. It did not contain a randomized active comparison group.
The efficacy analysis included 65 patients. Independent reviewers measured tumor response and response duration.
About fifty-two percent had an objective response. That finding is distinct from a demonstrated survival benefit.
The decision used accelerated approval. Continued verification of clinical benefit remained part of the pathway.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.